Decision Trees to Characterise the Roles of Permeability and Solubility on the Prediction of Oral Absorption
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
CASE REPORTS Rhabdomyolysis Following Cardiopulmonary Bypass and Treatment with Enoximone in a Patient Susceptible to Malignant
Ⅵ CASE REPORTS Anesthesiology 2001; 94:355–7 © 2001 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Rhabdomyolysis following Cardiopulmonary Bypass and Treatment with Enoximone in a Patient Susceptible to Malignant Hyperthermia Friedrich-Christian Riess, M.D.,* Marko Fiege, M.D.,† Sina Moshar, M.D.,‡ Heinz Bergmann, M.D.,§ Niels Bleese, M.D.,ʈ Joachim Kormann, M.D.,# Ralf Weißhorn, M.D.,† Frank Wappler, M.D.†† SEVERE hypercapnia, muscle rigidity, hyperthermia, and After implantation of a mechanical valve (Medtronic Hall; Medtronic, rhabdomyolysis characterize malignant hyperthermia Minneapolis, MN), the ascending aorta was closed and the aortic 1 cross-clamp removed. During reperfusion, the patient exhibited ST (MH) in fulminant form. However, during cardiac opera- Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/94/2/367/402332/0000542-200102000-00029.pdf by guest on 29 September 2021 elevations, with maximal values of 12 mV in all leads. The left ventricle tions using cardiopulmonary bypass (CPB), typical symp- appeared to be ischemic and hypokinetic. A triple bypass was per- toms of MH may not be present. We observed a patient formed using saphenous grafts to the left anterior descending, first undergoing aortic valve replacement, in whom severe post- diagonal branch and the circumflex artery. The patient was then operative rhabdomyolysis and arrhythmias developed after successfully weaned from CPB using a moderate dose of adrenalin (4 treatment with enoximone during CPB and cardioplegic g/min) and 50 mg enoximone (Perfan; Hoechst, Bad Soden am Ts., Germany). However, toward the completion of the operation, the arrest. Subsequently, in vitro contracture testing showed urine became dark and the minute ventilation necessary to maintain that the patient was susceptible to MH. -
(12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig. -
Prostate Cancer and Sexual Function
Prostate Cancer and Prostatic Diseases (1998) 1, 179 ±184 ß 1998 Stockton Press All rights reserved 1365±7852/98 $12.00 http://www.stockton-press.co.uk/pc Review Prostate cancer and sexual function RS Kirby,1 A Watson2 and DWW Newling3 1St. George's Hospital, London, UK; 2Watson Biomedical, Maidstone, UK; and 3Academisch Ziekenhuis der Vrije Universiteit, Amsterdam, The Netherlands Erectile dysfunction is a condition affecting 1 in every 10 men. Although its occurrence is related to ageing, illness and its necessary therapy can play a major role. Prostate cancer can lead to erectile dysfunction both psychologically through depression and emotional distress, and physically through therapy for the disease. An international quality of life survey involving 401 patients with prostate cancer was conducted. The objectives of the study were to investigate the patients' understanding of the treatment options they received, to explore the importance of the patient±doctor communication in the treatment of prostate cancer and to see what effect treatment had on patient's sexual function. One of the main ®ndings of the survey was that too little counselling or information on treatment options and their effects on sexual function was provided to patients. Patients themselves felt that psychosexual counselling, in particular, would be helpful. In addition, therapy for prostate cancer appears to have a signi®cant impact on patients' lifestyle and also on their libido, sexual function and activity. Keywords: prostate cancer; erectile dysfunction; quality -
Stems for Nonproprietary Drug Names
USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol -
Partial Agreement in the Social and Public Health Field
COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this -
Connecticut Medicaid
ACNE AGENTS, TOPICAL ‡ ANGIOTENSIN MODULATOR COMBINATIONS ANTICONVULSANTS, CONT. CONNECTICUT MEDICAID (STEP THERAPY CATEGORY) AMLODIPINE / BENAZEPRIL (ORAL) LAMOTRIGINE CHEW DISPERS TAB (not ODT) (ORAL) (DX CODE REQUIRED - DIFFERIN, EPIDUO and RETIN-A) AMLODIPINE / OLMESARTAN (ORAL) LAMOTRIGINE TABLET (IR) (not ER) (ORAL) Preferred Drug List (PDL) ACNE MEDICATION LOTION (BENZOYL PEROXIDE) (TOPICAL)AMLODIPINE / VALSARTAN (ORAL) LEVETIRACETAM SOLUTION, IR TABLET (not ER) (ORAL) • The Connecticut Medicaid Preferred Drug List (PDL) is a BENZOYL PEROXIDE CREAM, WASH (not FOAM) (TOPICAL) OXCARBAZEPINE TABLET (ORAL) listing of prescription products selected by the BENZOYL PEROXIDE 5% and 10% GEL (OTC) (TOPICAL) ANTHELMINTICS PHENOBARBITAL ELIXIR, TABLET (ORAL) Pharmaceutical and Therapeutics Committee as efficacious, BENZOYL PEROXIDE 6% CLEANSER (OTC) (TOPICAL) ALBENDAZOLE TABLET (ORAL) PHENYTOIN CHEW TABLET, SUSPENSION (ORAL) safe and cost effective choices when prescribing for HUSKY CLINDAMYCIN PH 1% PLEGET (TOPICAL) BILTRICIDE TABLET (ORAL) PHENYTOIN SOD EXT CAPSULE (ORAL) A, HUSKY C, HUSKY D, Tuberculosis (TB) and Family CLINDAMYCIN PH 1% SOLUTION (not GEL or LOTION) (TOPICAL)IVERMECTIN TABLET (ORAL) PRIMIDONE (ORAL) Planning (FAMPL) clients. CLINDAMYCIN / BENZOYL PEROXIDE 1.2%-5% (DUAC) (TOPICAL) SABRIL 500 MG POWDER PACK (ORAL) • Preferred or Non-preferred status only applies to DIFFERIN 0.1% CREAM (TOPICAL) (not OTC GEL) (DX CODE REQ.) ANTI-ALLERGENS, ORAL SABRIL TABLET (ORAL) those medications that fall within the drug classes DIFFERIN -
Maximum Androgen Blockade Does Not Confer Additional Survival Benefit to Androgen Suppression in Prostate Cancer
Evid Based Med: first published as 10.1136/ebm.6.1.17 on 1 January 2001. Downloaded from Review: maximum androgen blockade does not confer additional survival benefit to androgen suppression in prostate cancer Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000 Apr 29;355:1491–8. QUESTION: In men with prostate cancer, is maximum androgen blockade (MAB) better than androgen suppression (AS) alone for prolonging survival? Data sources Conclusion Studies were identified by searching computerised data- In men with advanced prostate cancer, the addition of bases, trial registers, meeting abstracts, and reference an antiandrogen to androgen suppression alone does lists and by contacting investigators and pharmaceutical not confer a statistically significant survival benefit at 5 companies. years. Study selection Studies were selected if they were randomised trials that COMMENTARY began before 1991 and compared MAB (AS plus an antiandrogen, such as nilutamide, flutamide, or cyprot- The Prostate Cancer Trialists’ Collaborative Group erone acetate) with AS alone and if the treatment was (PCTCG) study shows that adding a non-steroidal antian- given for >1 year. drogen (NSAA) to androgen suppression produces a statis- tically significant increase in long term survival over AS Data extraction alone. The real question is whether the difference of 2.9% (CI 0.4% to 5.4%) is clinically significant. The answer is, Information was requested for each patient on stage of “probably not.” disease, age at randomisation, date of randomisation, The issue hinges on symptoms and quality of life. Adding treatment allocation, date of last follow up, date of death, an NSAA to medical or surgical castration, thereby achiev- and cause of death. -
Anandron® (Nilutamide) Tablets 1 Name of the Medicine
AUSTRALIAN PRODUCT INFORMATION – ANANDRON® (NILUTAMIDE) TABLETS 1 NAME OF THE MEDICINE Nilutamide 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Nilutamide is a non-steroidal orally-active specific antiandrogen. Each ANANDRON tablet contains nilutamide 150 mg as active ingredient. Excipients with known effect: sugars as lactose monohydrate. For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Practically white, biconvex cylindrical tablet, approx. 10 mm in diameter, marked "168D" on one side with company logo "RU" on reverse side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS ANANDRON is indicated for the treatment of previously untreated metastatic prostatic carcinoma, in conjunction with surgical or medical castration. ANANDRON prevents the disease flare associated with the use of LHRH agonists. 4.2 DOSE AND METHOD OF ADMINISTRATION ANANDRON tablets are taken orally as either a once daily dose or as divided daily doses. To achieve maximum benefits, treatment should begin on the day of medical castration (eg. using an LHRH agonist) or surgical castration and continue without interruption. The following dosages are recommended, irrespective of renal function: Initial treatment The dosage for the first four weeks of treatment is 300 mg per day administered either as a once daily dose or as divided doses (eg. 150 mg twice daily). After four weeks, maintenance anandron-ccdsv5-piv4-11dec20 1 treatment should be commenced (see below). Maintenance treatment may be commenced earlier if undesirable effects, especially vomiting or visual effects, occur. Maintenance treatment Immediately following four weeks of initial treatment, the dosage is reduced to 150 mg per day administered as a once daily dose. -
Enhancement of Acetylcholinesterase Inhibitory Activity for the Soft Coral Associated Fungus Aspergillus Unguis SPMD-EGY by Media Composition
Int. J. Pharm. Sci. Rev. Res., 41(2), November - December 2016; Article No. 64, Pages: 349-357 ISSN 0976 – 044X Research Article Enhancement of Acetylcholinesterase Inhibitory Activity for the Soft Coral Associated Fungus Aspergillus unguis SPMD-EGY by Media Composition Faten K. Abd El-Hady1*, Mohamed S. Abdel-Aziz2, Ahmed M.A. Souleman3, Zeinab A. El-Shahid1, Kamel H. Shaker4 1Chemistry of Natural Products Department, National Research Center, Egypt. 2Department of Microbial Chemistry, National Research Center, Egypt. 3Department of Phytochemistry and Plant Systematic, National Research Center, Egypt. 4Chemistry of Natural Compounds Department, National Research Center, Egypt. *Corresponding author’s E-mail: [email protected] Accepted on: 24-09-2016; Finalized on: 30-11-2016. ABSTRACT The soft coral fungus, Aspergillus unguis SPMD-EGY, was grown on different media to select the potential medium producing significant high acetyl-cholinesterase (AChE) inhibitory activity. Extract from Rice solid medium exhibited the highest inhibitory activity of AChE followed by PYMG medium in static conditions (culture filtrate and mycelia). Potato dextrose broth (PD) showed no AChE inhibitory activity but moderate activity was found with DOX broth medium under static conditions (culture filtrate and mycelia). Comparative study has been done for PYMG medium and our previous work. The chemical composition of the potent extracts was evaluated using GC/MS analysis. Rice solid medium extract (RS, 89% AChE inhibitory activity) solely contains nitrogenous compounds, fatty acids and their esters. PYMG medium(PY, 85% activity) showed the presence of two major compounds: 1,3-bis[2-hydroxyphenyl]-2-propen-1-one (33.6%) and D-friedoolean-14-en-3-one (39.8%), mild presence for the compounds 1,6,7-trimethyl-3-phenyl-9H-xanthen-9-one (3%) and 2,4,4’-trihydroxy-chalcone (3.2%). -
Drug Therapy of Heart Failure
Drug Therapy of Heart Failure Objectives: ❖ Describe the different classes of drugs used for treatment of acute & chronic heart failure & their mechanism of action. ❖ Understand their pharmacological effects, clinical uses, adverse effects & their interactions with other drugs. Important In male and female slides helpful video Only in male slides Only in female slides Extra information Editing file -The inability of the heart to maintain an adequate cardiac output to meet the metabolic demands of the body. Causes (acute or chronic): - Heart valve disorder. - Abnormal heart rhythm. - High blood pressure. - Disorder of coronary arteries e.g. atherosclerosis - Cardiomyopathy. Symptoms: - Tachycardia. - Peripheral edema. - Cardiomegaly. - Dyspnea (Pulmonary congestion). - Decrease exercise tolerance (Rapid Fatigue). What is Heart Failure? The inability of the heart to maintain an adequate cardiac output to meet the metabolic demands of the body. Symptoms: Causes (acute or chronic): ● Tachycardia. ● Heart valve disorder. ● Cardiomegaly.Abnormal enlargement of heart ● High blood pressure. ● Decrease exercise tolerance ● Cardiomyopathy. (Rapid Fatigue). ● Abnormal heart rhythm. ● Peripheral edema. ● Disorder of coronary arteries ● Dyspnea (Pulmonary e.g. atherosclerosis congestion). PATHOPHYSIOLOGY OF CHF When there is low CO it will cause the heart to undergo compensatory responses* ↓ Force of contraction Factors affecting cardiac output and heart failure: 1-Preload. 2-Afterload. ↓ C.O 3-Cardiac contractility. ↓ Arterial pressure (BP) ↓ Renal -
Phosphodiesterase Inhibitors: Their Role and Implications
International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.1, No.4, pp 1148-1160, Oct-Dec 2009 PHOSPHODIESTERASE INHIBITORS: THEIR ROLE AND IMPLICATIONS Rumi Ghosh*1, Onkar Sawant 1, Priya Ganpathy1, Shweta Pitre1 and V.J.Kadam1 1Dept. of Pharmacology ,Bharati Vidyapeeth’s College of Pharmacy, University of Mumbai, Sector 8, CBD Belapur, Navi Mumbai -400614, India. *Corres.author: rumi 1968@ hotmail.com ABSTRACT: Phosphodiesterase (PDE) isoenzymes catalyze the inactivation of intracellular mediators of signal transduction such as cAMP and cGMP and thus have pivotal roles in cellular functions. PDE inhibitors such as theophylline have been employed as anti-asthmatics since decades and numerous novel selective PDE inhibitors are currently being investigated for the treatment of diseases such as Alzheimer’s disease, erectile dysfunction and many others. This review attempts to elucidate the pharmacology, applications and recent developments in research on PDE inhibitors as pharmacological agents. Keywords: Phosphodiesterases, Phosphodiesterase inhibitors. INTRODUCTION Alzheimer’s disease, COPD and other aliments. By cAMP and cGMP are intracellular second messengers inhibiting specifically the up-regulated PDE isozyme(s) involved in the transduction of various physiologic with newly synthesized potent and isoezyme selective stimuli and regulation of multiple physiological PDE inhibitors, it may possible to restore normal processes, including vascular resistance, cardiac output, intracellular signaling selectively, providing therapy with visceral motility, immune response (1), inflammation (2), reduced adverse effects (9). neuroplasticity, vision (3), and reproduction (4). Intracellular levels of these cyclic nucleotide second AN OVERVIEW OF THE PHOSPHODIESTERASE messengers are regulated predominantly by the complex SUPER FAMILY superfamily of cyclic nucleotide phosphodiesterase The PDE super family is large, complex and represents (PDE) enzymes. -
The Role of Highly Selective Androgen Receptor (AR) Targeted
P h a s e I I S t u d y o f I t r a c o n a z o l e i n B i o c h e m i c a l R e l a p s e Version 4.0: October 8, 2014 CC# 125513 CC# 125513: Hedgehog Inhibition as a Non-Castrating Approach to Hormone Sensitive Prostate Cancer: A Phase II Study of Itraconazole in Biochemical Relapse Investigational Agent: Itraconazole IND: IND Exempt (IND 116597) Protocol Version: 4.0 Version Date: October 8, 2014 Principal Investigator: Rahul Aggarwal, M.D., HS Assistant Clinical Professor Division of Hematology/Oncology, Department of Medicine University of California San Francisco 1600 Divisadero St. San Francisco, CA94115 [email protected] UCSF Co-Investigators: Charles J. Ryan, M.D., Eric Small, M.D., Professor of Medicine Professor of Medicine and Urology Lawrence Fong, M.D., Terence Friedlander, M.D., Professor in Residence Assistant Clinical Professor Amy Lin, M.D., Associate Clinical Professor Won Kim, M.D., Assistant Clinical Professor Statistician: Li Zhang, Ph.D, Biostatistics Core RevisionHistory October 8, 2014 Version 4.0 November 18, 2013 Version 3.0 January 28, 2013 Version 2.0 July 16, 2012 Version 1.0 Phase II - Itraconazole Page 1 of 79 P h a s e I I S t u d y o f I t r a c o n a z o l e i n B i o c h e m i c a l R e l a p s e Version 4.0: October 8, 2014 CC# 125513 Protocol Signature Page Protocol No.: 122513 Version # and Date: 4.0 - October 8, 2014 1.